

EXPLORING PATHOLOGIST-PATHOLOGIST AGREEMENT AS A BASELINE FOR ALGORITHM-PATHOLOGIST AGREEMENT

Brandon D. Gallas

Division of Imaging, Diagnostics, Software Reliability

Office of Science and Engineering Laboratories Center for Devices and Radiological Health U.S. Food and Drug Administration

Collaborators

- Mohamed Amgad, MD
 - Department of Pathology, Northwestern University
- Kim Blenman, PhD
 - Yale School of Medicine
- Weijie Chen, PhD
 - FDA/CDRH/OSEL/DIDSR
- Sarah Dudgeon, MPH
 - CORE Center for Computational Health Yale-New Haven Hospital
- Kate Elfer, MPH
 - FDA/CDRH/OSEL/DIDSR
- Victor Garcia, MD
 - FDA/CDRH/OSEL/DIDSR
- Rajarsi Gupta, MD/PhD
 - Stony Brook Medicine Dept of Biomedical Informatics
- Matthew Hanna, MD
 - Memorial Sloan Kettering Cancer Center
- Steven Hart, PhD
 - Department of Health Sciences Research, Mayo Clinic
- Evangelos Hytopoulos, PhD
 - iRhythm Technologies Inc
- Denis Larsimont, MD
 - Department of Pathology, Institut Jules Bordet

- Xiaoxian Li, MD/PhD
 - Emory University School of Medicine
- Anant Madabhushi, PhD
 - Case Western Reserve University
- Hetal Marble, PhD
 - Massachusetts General Hospital/Harvard Medical School
- Roberto Salgado, PhD
 - Division of Research, Peter Mac Callum Cancer Centre, Melbourne, Australia; Department of Pathology, GZA-ZNA Hospitals
- Joel Saltz, MD/PhD
 - Stony Brook Medicine Dept of Biomedical Informatics
- Manasi Sheth, PhD
 - FDA/CDRH/OPQE/Division of Biostatistics
- Rajendra Singh, MD
 - Northwell health and Zucker School of Medicine
- Evan Szu, PhD
 - Arrive Bio
- Darick Tong, MS
 - Arrive Bio
- Si Wen, PhD
 - FDA/CDRH/OSEL/DIDSR
- Bruce Werness, MD
 - Arrive Bio

JSM 2021, Medical Devices and Diagnostics Speed Session, Gallas and Elfer, Pathologist Agreement

Outline

- Clinical Context: Imaging Biomarker
- Initial Analysis of Pilot Study
- Quantitative Agreement
 - Bland-Altman ... Limits of Agreement
- Strategy to Use Thresholds
 - Binary Crowd-Expert Agreement for each Expert
 - Then Average over Experts
 - Baseline performance: Expert-Expert Agreement

FD

Clinical Context and Relevance

- Clinical context:
 - Breast cancer
 - Quantitative Pathology Biomarker: Stromal Tumor Infiltrating Lymphocytes (sTILs)
- Clinical relevance of sTILs:
 - Prognostic for survival
 - Expected to inform patient management
 - Expected to reduce use of toxic chemotherapies
- Biomarker Evaluation by an Algorithm
 - Reduce burden on pathologist
 - Reproducible
 - Quantitative



- Deliverables
 - Reference standard data from pathologists
 - Methods to validate a quantitative algorithm

FDA.gov

JSM 2021, Medical Devices and Diagnostics Speed Session, Gallas and Elfer, Pathologist Agreement

OSEL Accelerating patient access to innovative, safe, and effective medical devices through best-in-the-world regulatory science



Pilot Study

- 64 H&E Slides
- 10 Regions of Interest (ROIs) per Slide
- Some ROIs are not appropriate for sTIL evaluation
- Evaluation Platforms:
 - 2 digital and 1 microscope
- Readers:
 - 37 readers
 - 7 crowd readers with complete data
 - 7 expert readers are on the collaboration team
- 7,898 Observations
 - <u>432 observations are from 6 experts</u> that completed "SELECT" subset of 72 ROIs





FDA.gov

Date and event description



• Mean and Variance are averages over all readers

OSEL Accelerating patient access to innovative, safe, and effective medical devices through best-in-the-world regulatory science



- Mean and Variance are averages over all readers
- Vertical dashed lines represent clinical bins
 - low (≤ 10%)
 - medium (>10% & ≤ 40%)
 - high (>40%)Horizontal

OSEL Accelerating patient access to innovative, safe, and effective medical devices through best-in-the-world regulatory science



- Means and Variances are averages over all readers
- Vertical lines represent clinical bins
 - − low (≤ 10%)
 - medium (>10% & ≤ 40%)
 - high (>40%)
- Variance is increasing with the mean

Date and event description

OSEL Accelerating patient access to innovative, safe, and effective medical devices through best-in-the-world regulatory science



- Means and Variances are averages over all readers
- Vertical dashed lines represent clinical bins
 - low ($\leq 10\%$)
 - medium (>10% & ≤ 40%)
 - high (>40%)Horizontal
- The variance does not increase with mean in a standard way

Date and event description

OSEL Accelerating patient access to innovative, safe, and effective medical devices through best-in-the-world regulatory science



- If a crowd pathologist is an expert?
- If an AI/ML model is good enough?
- First thought
 - Bland-Altman Plots
 - Limits of Agreement (LOA)

FDA



FDA



FDA





- If a crowd pathologist is an expert?
- If an AI/ML model is good enough?
- First thought
 - Bland-Altman Plots
 - Limits of Agreement (LOA)
- Agreement of two pathologists
 - How do we incorporate multiple readers ... multiple experts?



Mean Difference (Bland-Altman) Plots for seven pathologists with complete pilot data



Mean Difference (Bland-Altman) Plots for seven pathologists with complete pilot data



Mean Difference (Bland-Altman) Plots for seven pathologists with complete pilot data



FDA.gov

19

FD

Date and event description





- Plot is symmetric by construction
 - Assume readers are equivalent
 - Difference 12:
 Reader 1 Reader 2
 - Difference 21:
 - Reader 2 Reader 1









Two readers

- Upper LOA = 12.1 %
- Mean diff = -2.9 %
- Lower LOA = -17.8 %

Seven readers, MRMC analysis

- Upper LOA = 17.8 %
- Mean diff = 0 (By construction)
- Lower LOA = -17.8 %

Date and event description

OSEL Accelerating patient access to innovative, safe, and effective medical devices through best-in-the-world regulatory science





- Differences not independent
 - Multiple readers, Multiple Cases
 - Fully-crossed data
- Differences not identically distributed
 - Differences increase with the mean



- Differences not independent
 - Multiple readers, Multiple Cases
 - Fully-crossed data
- Differences not identically distributed
 - Differences increase with the mean
 - Differences not normally distributed
 - Cone of maximum possible difference

FDA.gov

Date and event description

OSEL Accelerating patient access to innovative, safe, and effective medical devices through best-in-the-world regulatory science



How should we determine ...

- If a pathologist is an expert?
- If an AI/ML model is good enough?
- First thought
 - Bland-Altman Plots
 - Limits of Agreement (LOA)
- Assumptions not satisfied ... Good for exploratory analysis

 What next?



Crowd vs. Expert, nObs = 59



OSEL Accelerating patient access to innovative, safe, and effective medical devices through best-in-the-world regulatory science



Crowd vs. Expert, nObs = 59



- Crowd pathologist
 - Typical data
 - Substitute "Al Model"
- SELECT data
 - 72 cases, some labeled not evaluable
- Not clustered around diagonal
- Not normally distributed
- Not IID









		crowd	
		≤t	> t
Expert	>t	1	10
	≤t	30	18

FDA

FDA

Crowd-Expert Agreement

thr	esholc	l e	expert crowd		d	
	40	exp	expert2240		pathologist3254.camic	
	[cro	wd			
		≤t	> t	Row Total	Fraction Agree	Standard Error
ert	> t	1	10	11	0.91	0.0867
Exp	≤t	30	18	48	0.63	0.0699

Crowd-Expert Agreement

thr	esholc	expert			crowd		
	40	exp	expert224		0 pathologist3254.camic		
	[cro	wd				
		≤t	> t	Row Total	Fraction Agree	Standard Error	
ert	> t	1	10	11	0.91	0.0867	
Exp	≤t	30	18	48	0.63	0.0699	

- TPF = Fraction Agree "> t"
- FPF = Fraction Agree " \leq t"

- TPF and FPF understood to be
- Crowd-Expert Agreement
- Compare Crowd to all Experts



Crowd Agreement With Experts













FPF = 1- Specificity

Expert Crowd Agreement With Experts



0.6

FPF = 1- Specificity

0.4

0.8

1.0

Expert Crowd Agreement With Experts



FPF = 1- Specificity



OSEL Accelerating patient access to innovative, safe, and effective medical devices through best-in-the-world regulatory science

0.2

0.0



How should we determine ...

- If a pathologist is an expert?
- If an AI/ML model is good enough?
- Current Strategy
 - Compare crowd reader to all experts
 - Compare each expert to all other experts
 - Establish criteria for a crowd-expert agreement
 - Develop Multi-Expert Multi-Case (MEMC) analysis methods

Summary

FD

- Clinical Context: Imaging Biomarker
- Initial Analysis of Pilot Study
- Quantitative Agreement
 - Bland-Altman ... Limits of Agreement
- Strategy to Use Thresholds
 - Binary Crowd-Expert Agreement for each Expert
 - Then Average over Experts
 - Baseline performance: Expert-Expert Agreement
 - Develop Multi-Expert Multi-Case (MEMC) Analysis Methods

Conclusions

• Analyzing objective estimates of quantitative values from humans is hard!

- I object to referring to the estimates are "subjective"
- Not based on or influenced by personal feelings, tastes, or opinions
- They are noisy
- Data from humans violate assumptions for Limits of Agreement
 - Not normally distributed
 - Not independent and identically distributed
- Strategies that treat the data as ordinal can sidestep assumptions
 - Add calibration thresholds
 - Explore calibration thresholds

FDA.gov

Date and event description



CDRH Mission



effectiveness of medical devices and the safety of radiation-emitting electronic products...

We facilitate medical device innovation by advancing regulatory science, providing industry with predictable, consistent, transparent, and efficient regulatory pathways, and assuring consumer confidence in devices marketed in the U.S.



D



43

CDRH in Perspective

1900 EMPLOYEES	18k Medical Device Manufacturers	183k Medical Devices On the U.S. Market	
22k /year Premarket	570k Proprietary Brands	1.4 MILLION/year Reports on	
Submissions includes supplements and amendments	25k Medical Device Facilities Worldwide	adverse events and malfunctions	



ΛΛ

Office of Science and Engineering Laboratories (OSEL)

- Conduct laboratory-based regulatory research to facilitate development and innovation of safe and effective medical devices and radiation emitting products
- Provide scientific and engineering expertise, data, and analyses to support regulatory processes
- Collaborate with colleagues in academia, industry, government, and standards development organizations to develop, translate, and disseminate science and engineering-based information regarding regulated products
- <u>https://www.fda.gov/about-fda/cdrh-offices/office-science-and-engineering-laboratories</u>

OSEL in Perspective





Division of Imaging, Diagnostics and Software Reliability (DIDSR)

- Develop least burdensome approaches for regulatory evaluation of imaging and big-data devices
 - Efficient clinical trials accounting for reader variability, simulation tools, in silico phantoms and imaging trials, addressing issues related to imperfect / missing reference standards, and limited data for training/testing of machine classifiers
- Develop measures of technical effectiveness of imaging and big-data technologies
 - Phantoms, laboratory measurements, computational models

DIDSR in Perspective



35 FEDERAL EMPLOYEES 14 Fellows/Students 3 Open Staff Positions

145/year

Peer reviewed articles, code and presentations

4 Program Areas

- AI/ML
- Medical Imaging and Diagnostics
- Digital Pathology
- Mixed Reality (AR/VR/XR)

550/year

Premarket Regulatory consults

~15,000 ft²

